EUCTR2019-002632-90-PL进行中（未招募）1 期
A prospective, double-blind, randomised, placebo-controlled trial on the efficacy and safety of Neiromidin 20 mg tablets in the treatment of patients with lumbosacral radiculopathy
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Olainfarm AS
- 入组人数
- 458
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Male or female patients, aged 18-65 years old inclusive at the time of
- •signing the informed consent.
- •2)Low back pain irradiating through vertebral roots to lower limb (L5-S1
- •segments) and lasting for one to six (1-6) months before the enrolment
- •(based on medical history and medical records)and radicular leg pain of
- •moderate to severe intensity (NRS = 6) over the preceding week.
- •3)Diagnosis of lumbosacral radiculopathy supported with objective,
- •documented evidence of lumbosacral radiculopathy as evidenced by
- •imaging (magnetic resonance imaging or computed tomography, or Xray)
- •allowing to reject any significant non-degenerative spine injury.
- •4)ODI 16-60%.
- •5)Females of nonchildbearing potential (postmenopausal [defined as 12
- •months of spontaneous amenorrhea] or pre-menopausal with
- •documented irreversible surgical sterilization or hysterectomy) or
- •childbearing potential (negative pregnancy test at screening and using
- •an effective method to avoid pregnancy, i.e., oral, injectable,
- •transdermal or implanted hormonal contraceptives, vaginal
- •contraceptive ring, intrauterine device/intrauterine system,
- •vasectomised sexual partner [with confirmed negative sperm counts] or
- •true sexual abstinence).
- •6)Signed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 458
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A. Concomitant diseases or conditions
- •1)Hypersensitivity to ipidacrine and any of the excipients (i.e., lactose,
- •potato starch, calcium stearate, denatonium benzoate anhydrous,
- •Prosolv® EASYtab SP).
- •2)Contraindications to the use of ipidacrine:
- •extrapyramidal disorders with hyperkinesia,
- •angina pectoris,
- •significant bradycardia,
- •bronchial asthma,
- •intestinal or urinary tract obstruction,
- •exacerbation of gastric ulcer or duodenal ulcer,
- •vestibular disturbances,
- •pregnancy,
- •breast-feeding.
- •3)Rare hereditary problems of galactose intolerance, total lactase
- •deficiency or glucose-galactose malabsorption.
- •4)Cauda equina syndrome.
- •5)Bilateral lumbosacral radiculopathy.
- •6)Severely reduced muscle strength: grade 0 or 1 (Medical Research
- •Council [MRC] Muscle Scale grade) for foot flexors and/or foot extensors
- •and/or extensor hallucis longus of the affected side.
- •7)Demyelinating disease.
- •8)Any disease treated with systemic steroids and/or biological therapy
- •within 12 months before the enrolment.
- •9)Systemic or local infections within two weeks before the enrollment.
- •10)Clinically significant kidney or liver impairment (kidney impairment
- •assessed as eGFR < 45 ml/min/1.73 m², and liver impairment assessed
- •as > 3x upper normal limit for AST and/or ALT).
- •11)Implanted temporary transvenous cardiac pacemaker.
- •12)Inserted peripheral or central venous catheter or device with
- •external wires that are in close proximity to the heart.
- •13)Severe obesity (Body Mass Index > 40 kg/m2).
- •14)Current or previous malignancy of any location (except cured basal
- •cell carcinoma of the skin).
- •15)Immunosuppression or human immunodeficiency virus (HIV)
- •16)Evidence of any significant clinical or laboratory finding, or
- •electrocardiogram test results that make it undesirable for the patient to
- •participate in the study.
- •17)Lumbosacral radiculopathy onset due to a non-degenerative spine
- •18)Mental disease or high-risk for suicide (i.e., suicide attempts in the
- •past or current suicidal ideas).
- •B. Previous, concomitant or planned treatments
- •1)Post-surgery period (lumbosacral spine surgery) of less than three
- •months before the enrolment.
- •2)Surgical interventions planned in the next two months.
- •3)Ipidacrine or any other AChE inhibitor-based therapy within 30 days
- •before the enrolment.
- •4)Use of chiropractice (i.e., spinal manipulation performed on spinal
- •articulations: lumbosacral, sacroiliac, costotransverse and/or
- •costovertebral joints) for the treatment of lumbosacral radiculopathy
- 另有 14 项未显示
研究者
相似试验
进行中（未招募）
1 期
A prospective, double-blind, randomised, placebo-controlled trial on the efficacy and safety of Neiromidin 20 mg tablets in the treatment of patients with lumbosacral radiculopathyEUCTR2019-002632-90-LVOlainfarm AS458
进行中（未招募）
1 期
A prospective, double-blind, randomised, placebo-controlled trial on the efficacy and safety of Neiromidin 20 mg tablets in the treatment of patients with lumbosacral radiculopathyumbosacral radiculopathyEUCTR2019-002632-90-CZOlainfarm AS458
已完成
3 期
A double-blind, randomised, placebo-controlled study to evaluate the effect of an orally-dosed herbal extract, Testofen, for the treatment of Benign Prostatic Hyperplasia (BPH) symptoms in otherwise healthy males.ACTRN12615001242516Amanda Rao100
已完成
4 期
A double-blind, randomised, placebo-controlled study to evaluate the safety and efficacy of Sambucol liquid formulation to reduce the duration and severity of the common cold and flu symptoms in adults.Treatment of common coldTreatment of InfluenzaAlternative and Complementary Medicine - Herbal remediesInfection - Other infectious diseasesACTRN12615000506594Prof Luis Vitetta200
进行中（未招募）
1 期
A prospective, double-blind, randomised, placebo-controlled trial on the efficacy and safety of Neiromidin 20 mg tablets in the treatment of patients with lumbosacral radiculopathyEUCTR2019-002632-90-BGOlainfarm AS458